- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07772232
Comparison of Holmium Laser Enucleation of the Prostate and Robotic Water Jet Ablation for Benign Prostatic Hyperplasia
Prospective Randomized Controlled Comparison of Holmium Laser Enucleation of the Prostate With Robotic Water Jet Ablation
연구 개요
상태
상세 설명
This prospective, randomized controlled trial is designed to compare the safety, effectiveness, and long-term durability of Holmium Laser Enucleation of the Prostate (HoLEP) utilizing MOSES 2.0 technology with Robotic Water Jet Ablation (RWJA) performed using the Hydros Robotic System for the treatment of benign prostatic hyperplasia (BPH). The trial will enroll 100 men aged 50 to 80 years who present with moderate-to-severe lower urinary tract symptoms secondary to BPH and prostate volumes between 50 and 180 mL. Participants will be randomized in a 1:1 ratio to receive either HoLEP or RWJA and will be monitored for five years following treatment.
The primary objective is to compare objective measures of treatment efficacy and durability at 12 months, specifically changes in prostate volume, prostate-specific antigen (PSA) levels, urinary flow rate (Qmax), and post-void residual urine volume (PVR). Secondary objectives include assessment of perioperative outcomes, safety profiles, patient-reported urinary and sexual function, treatment durability, reintervention rates, and healthcare resource utilization. Outcomes will be measured using validated instruments, such as the International Prostate Symptom Score (IPSS), Sexual Health Inventory for Men (SHIM), Male Sexual Health Questionnaire-Ejaculatory Dysfunction (MSHQ-EjD), and Incontinence Severity Index (ISI).
Although both procedures are established and FDA-approved therapies for BPH, direct comparative evidence is limited. This study seeks to address this evidence gap by generating high-quality comparative effectiveness data to inform clinical decision-making and patient counseling. The results may clarify the relative benefits and tradeoffs of each procedure, particularly in terms of symptom improvement, preservation of sexual function, durability of treatment response, and long-term healthcare utilization.
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Hazem Elmansy, MD
- 전화번호: 346-516-1481
- 이메일: hmelmansy@houstonmethodist.org
연구 연락처 백업
- 이름: Miguel Valdivia y Alvarado, MD
- 전화번호: 346-356-3622
- 이메일: mvaldiviayalvarado@houstonmethodist.org
연구 장소
-
-
Texas
-
Houston, Texas, 미국, 77030
- Houston Methodist
-
연락하다:
- Hazem Elmansy, MD
- 전화번호: 346-516-1481
- 이메일: hmelmansy@houstonmethodist.org
-
연락하다:
- Miguel Valdivia y Alvarado, MD
- 전화번호: 346-356-3622
- 이메일: mvaldiviayalvarado@houstonmethodist.org
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Male, age 50-80 years
- International Prostate Symptom Score (IPSS) ≥ 12
- Prostate size (TRUS): 50-180 mL
- Diagnosis of LUTS due to BPH
- Uroflow Qmax ≤ 15 mL/sec
- Mentally capable, able to comply with study procedures, written informed consent provided
- Able to follow study instructions and complete all required visits
Exclusion Criteria:
- BMI ≥ 42
- History of prostate cancer
- Suspected or history of bladder cancer
- Active or untreated bladder stones at screening
- Indwelling catheter for more than 3 months before baseline
- Active urinary tract infection
- History of urethral stricture or bladder neck stenosis
- Damage to the external urethral sphincter
- Previous prostate surgery or lower urinary tract surgery
- Use of obligatory anticoagulants (if not stoppable) or known coagulopathy (except ASA 100 mg/d)
- Contraindications to general and spinal anesthesia
- Any condition that could interfere with study participation or outcomes, per investigator judgment
- Lacks legal or mental capacity to consent
- Simultaneous participation in another therapeutic urological trial
- Known or persistent abuse of medication, drugs, or alcohol
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 다른
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: HoLEP with MOSES 2.0
Holmium laser enucleation of the prostate using MOSES 2.0 pulse-modulation technology, performed per institutional standard of care.
|
Holmium laser enucleation of the prostate using MOSES 2.0 pulse-modulation technology, performed per institutional standard of care.
|
|
활성 비교기: RWJA with Hydros Robotic System
Robotic-assisted waterjet ablation of the prostate using the Hydros Robotic System, performed per institutional standard of care.
|
Device - RWJA (Hydros Robotic System) / Aquablation therapy (often referred to by its commercial name, "Aquablation").
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in Prostate Volume
기간: Baseline and 12 months post-intervention
|
Measured via transrectal ultrasound (TRUS); change from baseline.
|
Baseline and 12 months post-intervention
|
|
Change in Prostate-Specific Antigen (PSA)
기간: Baseline and 12 months post-intervention
|
Serum PSA level; change from baseline.
|
Baseline and 12 months post-intervention
|
|
Change in Urinary Flow Rate (Qmax)
기간: Baseline and 12 months post-intervention
|
Peak urinary flow rate via uroflowmetry; change from baseline.
|
Baseline and 12 months post-intervention
|
|
Change in Post-Void Residual Volume (PVR)
기간: Baseline and 12 months post-intervention
|
Bladder scan-measured PVR; change from baseline.
|
Baseline and 12 months post-intervention
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence and Severity of Adverse Events
기간: From patient hospital discharge through 3 and 12 months post-surgery
|
Adverse events graded by the Clavien-Dindo classification system.
|
From patient hospital discharge through 3 and 12 months post-surgery
|
|
Operative Time
기간: Day (duration) of surgical procedure
|
Total procedure time, start to finish.
|
Day (duration) of surgical procedure
|
|
Hemostasis Time
기간: Day (duration) of surgical procedure
|
Time required to achieve hemostasis intraoperatively.
|
Day (duration) of surgical procedure
|
|
Perioperative Change in Hemoglobin
기간: Baseline to immediate postoperative period (when patient is in the recovery room post surgery)
|
Hemoglobin level change from baseline to immediate postoperative measurement.
|
Baseline to immediate postoperative period (when patient is in the recovery room post surgery)
|
|
Time to Catheter-Free Status
기간: From surgery day until catheter removal
|
Duration from end of surgery to catheter removal.
|
From surgery day until catheter removal
|
|
Length of Hospital Stay / Discharge Time
기간: Day of surgical procedure through hospital discharge
|
Time from surgery to hospital discharge.
|
Day of surgical procedure through hospital discharge
|
|
Change in IPSS/QoL Score
기간: Baseline, 3, 6, and 12 months post-surgery
|
International Prostate Symptom Score / Quality of Life index.
|
Baseline, 3, 6, and 12 months post-surgery
|
|
Change in SHIM Score
기간: Baseline, 3, 6, and 12 months post-surgery
|
Sexual Health Inventory for Men.
|
Baseline, 3, 6, and 12 months post-surgery
|
|
Change in MSHQ-EjD Score
기간: Baseline, 3, 6, and 12 months post-surgery
|
Male Sexual Health Questionnaire - Ejaculatory Dysfunction.
|
Baseline, 3, 6, and 12 months post-surgery
|
|
Change in Incontinence Outcomes
기간: Baseline, 3, 6, and 12 months post-surgery
|
Incontinence Severity Index (ISI) score and Cough Stress Test (CST) result.
|
Baseline, 3, 6, and 12 months post-surgery
|
|
Long-Term Durability of Functional Improvements
기간: 24, 36, 48, and 60 months post-intervention
|
Composite tracking of IPSS, Qmax, PVR, PSA, and prostate volume.
|
24, 36, 48, and 60 months post-intervention
|
|
Post-Operative Medication Use
기간: Through 60 months post-intervention
|
Number of prescriptions written and filled (initial fills and refills), e.g., alpha-blockers, 5-alpha reductase inhibitors.
|
Through 60 months post-intervention
|
|
Reintervention Rate
기간: Through 60 months post-intervention
|
Repeat procedures or additional therapies for BPH/LUTS.
|
Through 60 months post-intervention
|
|
Unplanned Healthcare Encounters
기간: Through 60 months post-intervention
|
Emergency visits, urgent care visits, and add-on clinic visits related to the procedure.
|
Through 60 months post-intervention
|
|
Incidence of Urethral Stricture Requiring Intervention
기간: Through 60 months post-intervention
|
New urethral stricture or bladder neck stenosis requiring treatment.
|
Through 60 months post-intervention
|
|
Unanticipated Advanced Diagnostics
기간: Through 60 months post-intervention
|
Unplanned MRI, cystoscopy, or prostate cancer biomarker testing.
|
Through 60 months post-intervention
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- Pro00041304
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .